Healthcare -
Biotechnology - NASDAQ - US
$ 4.6
-17.3 %
$ 314 M
Market Cap
-2.09
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Olema Pharmaceuticals, Inc.
| Net Income | -129 M |
| Depreciation & Amortization | 393 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 22.6 M |
| Change in Working Capital | 9.16 M |
| Others | -362 K |
| Free Cash Flow | -105 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (129.5) | (96.7) | (104.8) | (71.1) | (22.1) | (4.3) | (2.2) |
| Depreciation & Amortization | 0.4 | 0.4 | 0.4 | 0.2 | 11 K | 9 K | 8 K |
| Deferred Income Tax | 0 | 0 | 0 | 0.3 | 0 | 0 | 0 |
| Stock Based Compensation | 22.6 | 17.3 | 18.8 | 15.9 | 3.1 | 0 | 1 K |
| Other Operating Activities | (7.0) | (4.1) | 0.5 | 1.2 | 0.6 | (1.1) | 0.1 |
| Change in Working Capital | 9.2 | (0.6) | 3.0 | 2.8 | (1.5) | 1.2 | (0.1) |
| Cash From Operations | (104.4) | (83.7) | (82.1) | (50.7) | (19.9) | (3.1) | (2.2) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 0 | 0 | (0.4) | (1.6) | 56 K | 0 | 0 |
| Other Items | (93.5) | (4.9) | 91.8 | (273.9) | 0 | 0 | 0 |
| Cash From Investing Activities | (93.5) | (4.9) | 91.5 | (275.4) | 56 K | 0 | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (2.3) | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 3.1 | 0 | 0.3 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.5 | 3.7 | 0.5 | 1.4 | 134.8 | 0 | 9.9 |
| Cash From Financing Activities | 268.8 | 133.4 | 0.5 | 1.4 | 358.4 | 0 | 5.3 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 70.9 | 44.8 | 9.9 | (324.7) | 338.5 | (3.1) | 3.1 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (104.5) | (83.7) | (82.4) | (52.3) | (19.9) | (3.1) | (2.2) |